Ethiopian Pharmaceutical Manufacturing Sh. Co.

epharmsc.com

The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

news image

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More

Business Insights

OMNICELL COMPLETES ACQUISITION OF RECEPT

Omnicell, Inc. | December 30, 2021

news image

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, has completed the previously announced acquisition of ReCept Holdings, Inc. The addition of ReCept’s specialty pharmacy management services for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio to address the growing and complex specialty pharmacy market. ReCept provides implemen...

Read More

Business Insights

CLEARMIND MEDICINE TO PARTNER WITH MICRODOSE FOR PSYCHEDELIC CAPITAL

Clearmind Medicine Inc. | March 25, 2022

news image

Clearmind Medicine Inc. a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event. While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders. ...

Read More

Research, Business Insights

ALLUCENT EXTENDS MEDIDATA CLINICAL CLOUD USAGE TO EXPEDITE NEW DRUG DEVELOPMENT

Medidata Solutions | March 13, 2023

news image

Medidata, a leading provider of innovative software solutions for clinical trials that streamline the clinical trial process, reduce time and cost, and accelerate the development of new treatments, recently announced that Allucent, a contract research organization (CRO) that brings innovation to biopharma firms, is expanding the global use of Medidata's Clinical Cloud to enhance its clinical trial operations offering. This agreement extends Allucent's current usage of Me...

Read More
news image

Business Insights

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More
news image

Business Insights

OMNICELL COMPLETES ACQUISITION OF RECEPT

Omnicell, Inc. | December 30, 2021

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, has completed the previously announced acquisition of ReCept Holdings, Inc. The addition of ReCept’s specialty pharmacy management services for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio to address the growing and complex specialty pharmacy market. ReCept provides implemen...

Read More
news image

Business Insights

CLEARMIND MEDICINE TO PARTNER WITH MICRODOSE FOR PSYCHEDELIC CAPITAL

Clearmind Medicine Inc. | March 25, 2022

Clearmind Medicine Inc. a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event. While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders. ...

Read More
news image

Research, Business Insights

ALLUCENT EXTENDS MEDIDATA CLINICAL CLOUD USAGE TO EXPEDITE NEW DRUG DEVELOPMENT

Medidata Solutions | March 13, 2023

Medidata, a leading provider of innovative software solutions for clinical trials that streamline the clinical trial process, reduce time and cost, and accelerate the development of new treatments, recently announced that Allucent, a contract research organization (CRO) that brings innovation to biopharma firms, is expanding the global use of Medidata's Clinical Cloud to enhance its clinical trial operations offering. This agreement extends Allucent's current usage of Me...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us